1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Newbury expands its portfolio with two ready to launch products

Newbury Pharmaceuticals is pleased to announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in Sweden.

“I am pleased to announce the addition of two new products to our portfolio and in particular that these two products will be available for commercialization already in 2023.” Says Mr. Lars Minor, CEO of Newbury.

Both products are sourced from new partners to Newbury and based on a Distribution and Marketing agreement where Newbury will perform the commercialization in the territory.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury expands its portfolio with two ready to launch products

Datum 2022-11-23, kl 09:30
Källa MFN
Bifogade filer
Newbury expands its portfolio with two ready to launch products
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.